Glenmark Pharmaceuticals has made a remarkable turnaround in the fourth quarter of FY2025, surprising the market and rewarding its investors. Once grappling with heavy losses, the company has now reported a net profit and announced a massive 250% dividend for its shareholders.
From Loss to Profit
For the quarter ending March 31, 2025, Glenmark posted a net profit of ₹4.7 crore, a sharp reversal from a loss of ₹1,218 crore in the same quarter last year. This impressive comeback has restored investor confidence and market sentiment around the company.
Strong Growth in Revenue and Operating Profit
Quarterly Revenue: ₹3,256 crore (up 6.3% YoY)
Operating Profit: ₹561 crore (up 11% YoY)
EBITDA Margin Improvement: From 16.5% to 17.2%
The entire fiscal year has been a success story for Glenmark. The company's annual operating profit nearly doubled, rising from ₹1,195.3 crore to ₹2,351 crore — a stellar 96.7% growth. Annual revenue also saw a robust 12.8% jump.
Big Returns for Shareholders
The company has recommended a dividend of ₹2.50 per share, amounting to 250%, pending approval at the upcoming annual general meeting. Although Glenmark's shares ended slightly lower in the latest trading session, the stock has delivered a solid 38% return over the past year.
Conclusion
Glenmark Pharma's performance is a powerful example of a strategic turnaround in the Indian pharmaceutical sector. With disciplined financial management, operational efficiency, and a renewed growth trajectory, the company has shifted from losses to profitability. For shareholders and market watchers, Glenmark’s comeback is not just a quarterly success — it's a statement of resilience and renewed potential.
.jpg)